Melanocortin-1 Receptor (MC1R)
MC1R is the G protein-coupled receptor on melanocytes that, when bound by alpha-MSH or ACTH, raises cyclic AMP and switches pigment synthesis from pheomelanin toward eumelanin.
The melanocortin-1 receptor is the melanocortin GPCR expressed most heavily on melanocytes. Its ligands, alpha-melanocyte-stimulating hormone and ACTH, come from the same proopiomelanocortin precursor. Binding couples through Gs to adenylyl cyclase, raises cyclic AMP and induces MITF, the transcription factor driving the pigment enzymes. The output is a switch: strong signalling favours brown-black eumelanin, weak signalling leaves the cell making red-yellow pheomelanin, which absorbs ultraviolet poorly and generates radicals under it.
MC1R is unusually polymorphic in people of northern European ancestry. Three loss-of-function variants, written R151C, R160W and D294H, are the classic red-hair-colour alleles; carriers tan poorly, burn readily and carry higher melanoma risk. The receptor has one approved ligand: afamelanotide, an alpha-MSH analogue given as a subcutaneous implant, authorised by the EMA in 2014 and the FDA in 2019 for erythropoietic protoporphyria, on an endpoint of pain-free time in sunlight rather than cosmetic tanning.
Because the family also sits on immune cells and in the hypothalamus, melanocortin signalling is not only about colour: sibling receptors govern appetite, erectile function and sebum. Receptor selectivity therefore decides whether a melanocortin agonist is a pigment agent or a systemic drug.
The recurring error is treating grey-market tanning peptides as MC1R-selective. The circulated ones are broad agonists hitting MC3R, MC4R and MC5R too, hence the nausea, flushing, spontaneous erections and blood-pressure changes users describe. None is approved anywhere for cosmetic tanning, and darkening of existing naevi under a non-selective agonist complicates the melanoma surveillance variant carriers most need.